A Patient with Everolimus-Associated Pneumonitis
نویسندگان
چکیده
Interstitial pneumonitis has been observed as adverse effect in patients under immunosuppressive treatment with Sirolimus. Everolimus is the successor of Sirolimus and complications are less known. We report a case of pneumonitis that was observed in a patient with a kidney transplant and immunosuppression by Everolimus. The patient recovered after Everolimus was suspended, suggesting that it causes interstitial pneumonitis similar to Sirolimus.
منابع مشابه
Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
Everolimus is an inhibitor of mammalian target of rapamycin with anti-tumour activity. While everolimus is known to cause drug-induced pneumonitis, it is rarely associated with Pneumocystis jirovecii pneumonia (PJP). We report a patient on everolimus therapy for metastatic breast cancer that developed PJP. Diagnosis was based on clinical features and a quantitative polymerase chain reaction for...
متن کاملPolymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer
PURPOSE Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves increased progression free survival (PFS) compared with exemestane. However, there is great inter-patient variability in toxicity and response to exemestane-everolimus treatment. The objective of this study was to pe...
متن کاملSafety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC)
Renal cell carcinoma (RCC) is one of the most lethal genitourinary malignancies. Recently, there has been a paradigm shift in the management of advanced RCC. New targeted therapies including vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors have been developed which have shown promising results in a patient population who otherwise had very few option...
متن کاملAdverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.
BACKGROUND Everolimus, an orally administered rapamycin analogue, inhibits the mammalian target of rapamycin (mTOR), a highly conserved intracellular serine-threonine kinase that is a central node in a network of signaling pathways controlling cellular metabolism, growth, survival, proliferation, angiogenesis, and immune function. Everolimus has demonstrated substantial clinical benefit in rand...
متن کاملA Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer
LESSONS LEARNED The combination of everolimus and low-dose prednisone administered daily was hypothesized to prevent noninfectious pneumonitis (NIP) and mucositis, two common adverse events related to everolimus. Although mucositis was detected in only one case, all-grade NIP occurred in four of eight cases (50%), and this was considered enough to stop accrual of the study.These data suggest th...
متن کامل